CEO Helio Genomics объяснил, почему партнерства важнее науки для ранней диагностики рака

Dr. Bharat Tewarie is the CEO of Helio Genomics, focused on saving lives through early cancer detection. In cancer, timing is everything. That is especially true in liver cancer, where too many patients are still diagnosed after the window for curative treatment has narrowed or closed. For patients with cirrhosis, routine surveillance is meant to catch cancer early. But the current standard, ultrasound, can be difficult to complete consistently and may miss the smallest tumors—the very ones where early intervention can matter most. Companies are trying to help close the gaps across many different kinds of cancer, including my company. To support our work with our blood test, we lined up several established partners to help reduce our commercialization risk. Here’s what I have learned about creating successful partnerships in this industry. Partnerships To Add Scale And Reduce Execution Risk Strong trial results create credibility, but they do not automatically create adoption. That is where the business strategy becomes as important as the science. Collaborations can provide expertise, experience and scale, accelerating the shift from scientific validation to commercial adoption. For example, we partnered with a provider of laboratory diagnostic services, which gave healthcare providers a familiar ordering pathway through its provider network and integration into existing physician workflows. We also partnered with a contract commercialization organization to help drive physician and patient awareness, adoption and uptake, materially reducing our go-to-market risk. Before approaching potential partners, leaders should first map their own gaps with precision, such as distribution, reimbursement navigation, sales force coverage or workflow integration, and seek counterparts whose core strengths directly close those gaps rather than dilute focus. Cultural fit and shared sense of urgency matter as much as capability; in regulated diagnostics, a partner who understands the difference between promising data and reimbursable, physician-trusted tools is essential. In the early stages, invest in joint working sessions that define clear success metrics, decision rights and escalation paths. Establish a single point of accountability on each side, and run a short pilot or limited geography before full commitment. The most valuable lesson I have learned on reducing execution risk is this: Partnerships succeed when both parties treat the relationship as an extension of their own operating model, not as an outsourced function. Transparency on timelines, data sharing protocols and potential conflicts of interest from day one prevents the quiet erosion of trust that so often derails commercialization. The clearest takeaway: Choose partners who close real gaps and treat the alliance as shared execution, not a handoff. Finding The Right Partnership Mix The access story also matters beyond major medical centers. For example, a separate collaboration is set to broaden our access story by targeting rural populations, where traditional liver cancer surveillance can be harder to deliver consistently. For business leaders, the partnership mix underscores a broader lesson on why early cancer detection needs more than good science: Innovation in healthcare also requires the infrastructure to reach patients reliably and equitably. A strong partnership mix deliberately balances scale players that deliver national reach with specialized collaborators that unlock underserved segments or unique channels. The goal is complementary coverage without overlapping incentives that create friction. Managing multiple relationships simultaneously requires disciplined prioritization: Designate an internal owner for each alliance, maintain a living dashboard of milestones and risks, and schedule regular cross-partner alignment only when it creates real value rather than meetings for their own sake. Common challenges include resource stretch, conflicting partner priorities and the temptation to over-promise in the early enthusiasm phase. Address these by setting explicit capacity limits, building contingency clauses into agreements and resisting the urge to announce every collaboration before operational readiness is proven. Leaders should avoid treating partnerships as press-release opportunities first and operational realities second; I have noticed the companies that scale are those that protect execution bandwidth as carefully as they protect intellectual property. The Need For Execution, Not Just Innovation Working with experienced commercial partners can lower a company’s commercial-risk profile in a competitive field and is central to a strengthening business case: Diagnostics companies that pair credible clinical evidence with distribution, reimbursement and commercial adoption support are often better positioned to move from promising science to revenue-generating scale. After all, strong science matters, but partnerships and execution determine whether innovation reaches patients. That combination is the real story, and it may be the playbook for the next generation of early cancer detection. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?